OFFICERS

President
Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Immediate Past President
Roy A. Jensen, MD
The University of Kansas Cancer Center

Vice President/President-elect
Robert A. Winn, MD
VCU Massey Cancer Center

Treasurer
Jeff A. Walker, MBA
Roswell Park Comprehensive Cancer Center

Executive Director
Jennifer W. Pegher, MA
Association of American Cancer Institutes

NEW OFFICER

David M. Gosky, MA, MBA
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

BOARD OF DIRECTORS

Carlos L. Arteaga, MD
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

S. Gail Eckhardt, MD, FASCO
Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School

Randall F. Holcombe, MD, MBA
The University of Vermont Cancer Center

Thomas P. Loughran, Jr., MD
University of Virginia Cancer Center

Leonidas C. Platanias, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Anil K. Rustgi, MD
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Cornelia Ulrich, PhD, MS
Huntsman Cancer Institute
University of Utah

NEW BOARD MEMBERS

Marcia Cruz-Correa, MD, PhD
University of Puerto Rico
Comprehensive Cancer Center

Ruben A. Mesa, MD
Mays Cancer Center at UT Health San Antonio MD Anderson

Joann B. Sweasy, PhD
University of Arizona Cancer Center

Robert H. Vonderheide, MD, DPhil
Abramson Cancer Center of the University of Pennsylvania

The Association of American Cancer Institutes (AACI) represents 103 premier academic and freestanding cancer centers in the United States and Canada. AACI is accelerating progress against cancer by empowering North America’s leading cancer centers in their shared mission to alleviate suffering.
OF THE MANY LESSONS IMPARTED BY THE COVID-19 PANDEMIC, THE ABILITY TO ADAPT HAS BEEN ESPECIALLY VALUABLE FOR AACI MEMBERS. FOR THE SECOND YEAR, THE PANDEMIC PLAYED A MAJOR ROLE IN SHAPING AACI’S ACTIVITIES AND PRIORITIES; IT ALSO CATALYZED SIGNIFICANT CHANGES IN DAILY OPERATIONS AT AACI CANCER CENTERS, FROM TELEMEDICINE TO REMOTE MONITORING OF CLINICAL TRIALS.

In January 2021, AACI submitted a letter to President Biden outlining critical policy priorities for his administration’s first 100 days: addressing cancer disparities; reversing the damage of COVID-19 on cancer research, screening, and prevention; expanding coverage for telemedicine services; and strengthening funding for pediatric cancer initiatives. AACI also urged President Biden and leading state public health officials to prioritize patients with cancer and cancer survivors in the distribution and administration of COVID-19 vaccines.

AACI continued to take a strong position on the impact of systemic racism and other forms of discrimination on public health. The association redoubled its commitment to promoting diversity, equity, and inclusion (DEI) within North America’s leading cancer centers and in our communities. This year AACI also introduced the Cancer Health Equity Award, which was presented during the 2021 AACI/CCAF Annual Meeting to AACI Vice President/President-elect Dr. Robert A. Winn, director of VCU Massey Cancer Center.

As part of her presidential initiative focused on mitigating cancer health disparities, Dr. Karen E. Knudsen led an effort to collect and analyze data about the catchment areas that AACI cancer centers serve. In June, Dr. Knudsen stepped down as AACI president when she became chief executive officer of the American Cancer Society, and Dr. Caryn Lerman, director of University of Southern California (USC) Norris Comprehensive Cancer Center, began her presidency. Dr. Lerman’s presidential initiative, announced at the annual meeting, addresses another important aspect of DEI: diversifying the cancer leadership pipeline. We look forward to continuing to work with Dr. Lerman on this initiative and other projects.

Throughout the year AACI participated in activities to recognize the 50th anniversary of the National Cancer Act. To mark the anniversary, AACI invited Dr. Donald L. “Skip” Trump and journalist Eric T. Rosenthal, co-authors of *Centers of the Cancer Universe: A Half-Century of Progress Against Cancer*, to explore the association’s historical archives and highlight AACI’s origins, growth, and accomplishments.

Despite the many challenges of the past two years, AACI experienced continued growth in 2021. The association welcomed Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine to its roster, bringing its membership number to 103. Also in 2021, Fulgent Genetics joined the AACI Corporate Roundtable and Hematology/Oncology Pharmacy Association (HOPA) became an AACI sustaining member.

AACI extends its appreciation to our members, whose unwavering support helps advance our mission of accelerating progress against cancer.
Reflecting on President Joe Biden’s determination to “end cancer as we know it,” Dr. Sharpless said that eradicating all cancer may not be realistic, “but we think we can change the face of cancer, and the tragedy of cancer, as we know it today.” He added that he is optimistic that we can “dramatically decelerate” the annual rate of deaths from cancer in the U.S., which stands at approximately 600,000 per year.

Dr. Henry Ciolino, director of NCI’s Office of Cancer Centers, led a discussion about recent changes to guidelines for the Cancer Center Support Grant application, including requirements for consortium partners and research programs.

Of particular interest was the implementation of extensive plans to enhance diversity among cancer center membership and leadership. Asked whether underserved rural populations are being considered in promoting leadership diversity, Dr. Ciolino said that NCI weighed whether guidance should reflect the national population or cancer center catchment areas and decided on a national perspective. Whether centers in states like Oklahoma, Kansas, or Iowa should have rural representation in leadership remains an open question, he said, adding that developing leadership pipeline programs for high school students would be a step in that direction.

Reflecting on President Joe Biden’s determination to “end cancer as we know it,” Dr. Sharpless said that eradicating all cancer may not be realistic, “but we think we can change the face of cancer, and the tragedy of cancer, as we know it today.” He added that he is optimistic that we can “dramatically decelerate” the annual rate of deaths from cancer in the U.S., which stands at approximately 600,000 per year.

Dr. Henry Ciolino, director of NCI’s Office of Cancer Centers, led a discussion about recent changes to guidelines for the Cancer Center Support Grant application, including requirements for consortium partners and research programs.

Of particular interest was the implementation of extensive plans to enhance diversity among cancer center membership and leadership. Asked whether underserved rural populations are being considered in promoting leadership diversity, Dr. Ciolino said that NCI weighed whether guidance should reflect the national population or cancer center catchment areas and decided on a national perspective. Whether centers in states like Oklahoma, Kansas, or Iowa should have rural representation in leadership remains an open question, he said, adding that developing leadership pipeline programs for high school students would be a step in that direction.

WITH CONTINUED HEALTH CONCERNS AND RESTRICTIONS CAUSED BY THE CORONAVIRUS PANDEMIC, THE 2021 AACI/CCAF ANNUAL MEETING WAS HELD VIRTUALLY IN OCTOBER.

More than 500 cancer center members and other colleagues participated in the three-day event. Presentations covered a wide range of topics including telehealth; the impact of COVID-19 on cancer centers; computational oncology; cancer care across the lifespan; research at basic science cancer centers; and adapting clinical trials to patients’ changing needs.

Noting that racial and health equity have taken center stage in the national dialogue, Dr. Norman E. Sharpless, director of the National Cancer Institute (NCI), shared vignettes of patients who had trouble accessing cancer care. In the past year, he said, the NCI focused on persistent poverty as a major factor complicating access to care and found that overall cancer mortality is 12.3 percent higher in counties with persistent poverty than in non-persistent poverty counties.

Drs. Norman E. Sharpless and Caryn Lerman participate in a live Q&A during the 2021 AACI/CCAF Annual Meeting.
A panel discussion titled “Reducing Cancer Disparities: How to Ensure Durable Solutions” emphasized that cancer disparities manifest in many forms, from racism in prevention, screening, and genetic testing to a lack of diversity in clinical trials.

The panelists—Drs. Lucile Adams-Campbell, Chyke A. Doubeni, Chanita Hughes Halbert and moderator Dr. Robert A. Winn—identified an array of targeted measures as possible paths to reducing cancer disparities, including increasing the diversity of the cancer center workforce and research portfolio, instituting health equity report cards, and enhancing both trust among community members and the trustworthiness of cancer centers.


The 2022 AACI/CCAF Annual Meeting is slated to take place October 2–4 at the InterContinental at the Plaza in Kansas City, MO.

SERVICE TO CANCER RESEARCH

AACI recognized Dr. Robert Croyle for his service and dedication to the National Cancer Institute (NCI) and his contributions to cancer research and prevention. Dr. Croyle became director of NCI’s Division of Cancer Control and Population Sciences in 1998 and retired in 2021. Before joining NCI he was professor of psychology and a member of the Huntsman Cancer Institute at the University of Utah. Prior to that, he was a visiting investigator at the Fred Hutchinson Cancer Research Center.

NCA 50TH ANNIVERSARY

In his presentation, Dr. Brawley noted that the act grew out of 10-20 years of hard lobbying, much of it done by Mary Lasker and the American Cancer Society.

“[T]hey frequently get credit for it, but the truth is a number of other organizations and individuals were involved,” he said. “AACI, which was founded in 1950, was a major force in passage of the National Cancer Act.”

Drs. Robert H. Vonderheide and Robert T. Croyle, Julie Schaum, and Drs. Otis W. Brawley and Michelle M. Le Beau participate in a panel session during the 2021 annual meeting.
Dr. Judy E. Garber, chief of the Division of Cancer Genetics and Prevention at the Dana-Farber Cancer Institute, received the 2021 AACI Distinguished Scientist Award.

A professor of medicine at Harvard Medical School, Dr. Garber was honored for her breakthrough research on the treatment of triple-negative or basal-like breast cancer. Her recent investigations of germline and somatic genetic markers to predict response to targeted therapies in breast cancer patients expand the field and are impacting clinical practices.

Dr. Garber is a member of the National Academy of Medicine, a past member of the National Cancer Institute Board of Counselors and the American Society for Clinical Investigation, and is the past president of the American Association for Cancer Research.

Recent AACI Distinguished Scientist honorees include Drs. William G. Kaelin, Jr.; Douglas Lowy; James Allison; Lewis Cantley; Brian Druker; Mary-Claire King; and Margaret R. Spitz.

Dr. Robert A. Winn, AACI's vice president/president-elect and director of VCU Massey Cancer Center, received the inaugural AACI Cancer Health Equity Award during the 2021 AACI/CCAF Annual Meeting. AACI recognized Dr. Winn for his passionate commitment to improving health equity and his significant positive impact on cancer care in Virginia.

Driven by a belief that community engagement is a central component of population health management, Dr. Winn is at the forefront of addressing health disparities, promoting health equity, and advocating for diversity and inclusion in cancer care at the national level. He currently serves as a principal investigator on several community-based projects funded by the National Institutes of Health and National Cancer Institute, including the All of Us Research Program. Dr. Winn also oversees the Diversity in Clinical Trials Career Development Program, a partnership with National Medical Fellowships and Bristol Myers Squibb Foundation.

Sidney and Caroline Kimmel received the 2021 AACI Champion for Cures Award, which recognizes transformational philanthropy that advances our shared vision of a future without cancer.

Over the past 25 years, the Kimmels have changed the course of cancer research and care in Philadelphia and across the nation. Since 1994, the Kimmels have given nearly $600 million for cancer research, including a gift of $10 million to Thomas Jefferson University to name its cancer center, igniting a five-fold growth in the number of its investigators. Because of the Kimmels, Jefferson has been a Philadelphia-area leader in oncology research, patient treatment, and education services.

Sidney Kimmel has remained actively engaged in the strategic vision and growth of the Sidney Kimmel Cancer Center and Caroline Kimmel serves as a member of the Sidney Kimmel Cancer Center Advisory Council.
PRESIDENTIAL INITIATIVES

MITIGATING CANCER DISPARITIES

Dr. Karen E. Knudsen stepped down as AACI president and began a new role as chief executive officer of the American Cancer Society on June 1.

Dr. Knudsen's presidential initiative aimed to convert understanding of cancer disparities across AACI centers into meaningful, measurable actions to improve the lives of patients with cancer. Dr. Knudsen and colleagues collected and analyzed data through two surveys designed to improve our understanding of the catchment areas covered by AACI cancer centers and their demographic makeup.

As of December 2021, a manuscript detailing the surveys’ findings was being considered for publication. The hope is that the manuscript will provide valuable information that cancer centers can use to address gaps in services and access to care.

网络关怀

Dr. Stanton L. Gerson’s presidential initiative culminated in the publication of a report in the *Journal of the National Comprehensive Cancer Network*. Dr. Gerson is lead author on the report, which highlighted the results of a survey on the status of care across cancer center networks, including the finding that such networks have the potential to increase patient satisfaction and outcomes and decrease treatment delays and risks.

DIVERSIFYING THE LEADERSHIP PIPELINE

Dr. Caryn Lerman began her term as AACI president four months early, on June 1. She used the extra time to develop a comprehensive plan for her presidential initiative. Recognizing the need to diversify the leadership pipeline at AACI cancer centers, Dr. Lerman is focusing her presidential initiative on leadership development with an emphasis on diversity.

Expanding on the initial data collected from a survey conducted by AACI and *The Cancer Letter* in 2020, Dr. Lerman and AACI distributed a survey to determine areas for improvement at AACI cancer centers, including better representation of women and underserved populations in leadership positions.

Next steps in the initiative include developing a toolkit of best practices for cancer centers covering leadership development, diversifying the leadership pipeline, and onboarding; hosting workshops for future cancer center leaders at AACI/CCAF annual meetings; and mentoring new directors of cancer centers.
THE AACI CLINICAL RESEARCH INNOVATION (CRI) PROGRAM IS A NETWORK FOR RESEARCH LEADERS TO DEVELOP AND SHARE BEST PRACTICES FOR THE EFFICIENT OPERATION OF CLINICAL TRIALS OFFICES (CTO) AT AACI CANCER CENTERS.

Fulfilling that goal, the 13th Annual AACI CRI Meeting, *Adapting Clinical Trials Offices for 2021 and Beyond*, drew more than 1,000 registrants from 84 cancer centers, industry, and corporate roundtable and sustaining members. The three-day virtual meeting focused on adapting clinical trials amid the pandemic.

Meeting highlights included a session titled “Community Outreach and Engagement: Knowing Your Catchment Area,” which examined methods for extending clinical trial access to the community, working with satellite sites, bridging the gap between rural communities and cancer centers, and eliminating barriers for patients visiting the main cancer center.

A meeting session co-moderated by Dr. Bhanu Pappu and Anne Schnatterly explored ways to optimize the CTO, including recruiting, training, retaining, and promoting qualified staff. Additional presenters were Dr. Brandi Showalter and Alison Ivey.

Other meeting topics included electronic medical records, workflow efficiencies, staff retention, multisite investigator-initiated trials, training and competency evaluation, trial activation and prioritization, and quality assurance and compliance.

CRI pursues a strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration.

**WINNING ABSTRACTS**

Sixty-two abstracts were submitted from 27 cancer centers for the 13th Annual AACI CRI Meeting.

With help from peer reviewers on CRI committees, the CRI steering committee selected three winning abstracts for formal presentation at the meeting. Presentations reflected creative and thoughtful methods that are being employed at AACI cancer centers to improve the clinical trials process.

**FIRST PLACE**

*Electronic Source Documentation in EPIC Reduces Key Audit Findings and Aids in Remote Coordinating and Auditing*

N. Kurtzwell, M. Marcum, T. Wise-Draper
*University of Cincinnati Cancer Center*

**SECOND PLACE**

*A Catalyst for Success: How the 12T3 is Transforming IIT Development at UHCCC*

E. Monari, A. Ivey, T. George, A. Anderson
*University of Florida Health Cancer Center*

**THIRD PLACE**

*Doing More with Less: The Adoption of Slot Management Practices to Drive Resource Allocation in the Clinical Trials Office*

C. Gregor
*Vanderbilt-Ingram Cancer Center*
STEERING COMMITTEE WELCOMES NEW MEMBERS

Dr. Tara Lin, clinical trials office (CTO) medical director and associate professor of medicine, The University of Kansas Cancer Center, became chair of the CRI steering committee in September and four new members were elected: Dr. Rachna Shroff, The University of Arizona Cancer Center; Dr. Eneida Nemecek, OHSU Knight Cancer Institute; Susanna Sellman, Princess Margaret Cancer Centre; and Leslie P. Byatt, University of New Mexico Comprehensive Cancer Center. Kate Shumate, of the UCSF Helen Diller Family Comprehensive Cancer Center, ex officio, will represent the Cancer Center Administrators Forum (CCAF).

AACI thanks the following steering committee members who stepped down in 2021 for their time and commitment to CRI: Dr. Theresa L. Werner, Huntsman Cancer Institute, University of Utah; Melissa Nashawati, Mays Cancer Center at UT Health San Antonio MD Anderson; Collette M. Houston, Memorial Sloan Kettering Cancer Center; and Dr. Kimberly F. Kerstann, Winship Cancer Institute of Emory University.

SHARING A PATIENT PERSPECTIVE

Research advocate and health activist, Mary “Dicey” Jackson Scroggins, delivered the keynote presentation during the 13th Annual AACI CRI Meeting.

A 24-year ovarian cancer survivor and recent acute myeloid leukemia survivor, Scroggins is director of global outreach and engagement for the International Gynecologic Cancer Society; chair of the Advocacy Special Interest Group for the African Organisation for Research and Training in Cancer; and a co-founder of In My Sister’s Care, an organization focused on eliminating health disparities and improving gynecologic cancer awareness and care for medically underserved women.

During her presentation, which was supported by Caris Life Sciences, Scroggins shared “a patient perspective,” not “the patient perspective,” noting that patients’ experiences on clinical trials vary widely. She said that education on the purpose and value of clinical trials is key to improving public perception of clinical trials and earning trust from patients. Equally important are bidirectional communication between the patient and caregiver and ensuring that patients not only have access to a trial, but the opportunity to enroll.

LISTSERV

Throughout the pandemic, the CRI Listserv has been a valuable resource for cancer centers to discuss ways CTO staff are working remotely while maintaining trial treatments and safety monitoring. The listserv reaches more than 900 people at 89 AACI cancer centers.

Topics discussed in 2021 include: COVID-19 and trial recruitment; clinical trial activation metrics; budget negotiations and rate cards; Protocol Review Monitoring System policies for closing non-accreting trials and study termination; and regulatory staffing and expansion processes.
FACILITATING COLLABORATION

Clinical Trials Office (CTO)
Medical Directors Forum
The CTO Medical Directors Forum met monthly and held four roundtable discussions covering clinical disclosure agreements, trial site selection and expectations from industry, clinical trial budgeting and contracting, and recruitment and retention of CTO staff. The forum is creating a Memorandum of Understanding template for cancer centers to use with sponsors to receive compensation for work completed prior to finalizing the clinical trial agreement.

CTO Administrative Directors Forum
The CTO Administrative Directors Forum held its first roundtable in November. Over 50 members joined to hear how Huntsman Cancer Institute manages clinical trial volumes and prioritizes trials for activation. Members also discussed CTO resource needs and challenges faced with staffing, retention, training, and onboarding.

Education and Operations Subcommittee
The Education and Operations Subcommittee met bi-monthly to collect information about cancer center retention and training practices, specifically: retention policies, general orientation, and role-based clinical research training curriculum for new staff; career ladder programs for existing staff; and training outcomes and core competencies for new and promoted staff.

AACI Shared Investigator Platform (SIP) Task Force
The SIP Task Force met monthly in 2021. It created a SIP support webpage for AACI members and hosted informal meetings to answer questions about setting up SIP sites and user profiles. The task force members, Cognizant, and sponsors are drafting a survey to collect SIP user feedback.

AACI Corporate Roundtable (CRT) Task Force – Trial Activation
The AACI CRT Task Force is comprised of representatives from AACI’s Corporate Roundtable and the AACI CRI Steering Committee. Three working groups were created in March to continue discussions about improving trial activation timelines:

- Budget negotiations, including use of national coverage analysis
- Contract negotiations, including master trial agreements and confidentiality disclosure agreements
- Trial site committee reviews and communications, including the development of a common starting point with all stakeholders for the shared investigator platform, and site initiative visits
- The structure of the quality monitoring and assurance teams
- Biosimilars for oncolytic agents
PHYSICIAN CLINICAL LEADERSHIP INITIATIVE

THE 9TH ANNUAL PHYSICIAN CLINICAL LEADERSHIP INITIATIVE (PCLI) MEETING, HELD IN OCTOBER DURING THE 2021 AACI/CCAF ANNUAL MEETING, FEATURED A SESSION TITLED “CANCER CARE ACROSS THE LIFESPAN,” MODERATED BY DR. ANDREW CHAPMAN.

The presentations and discussion focused on pediatric, adult, and geriatric cancer patients. Speakers addressed biologic markers of aging, geriatric-driven interventions, palliative care, the importance of advocates for patients and families, and the administration of cancer treatment and care.

Panelists joining Dr. Chapman were

- Drs. Doug Fair, Tanyanika Phillips, and Ashley Rosko.

AACI established PCLI in 2013 as a forum for creating best practices to assist cancer center physician clinical leaders in addressing challenges like clinical services reimbursement, integrating electronic medical records with other cancer center IT services, assimilating clinical research and clinical programs to increase trial accrual, and developing performance metrics.

Dr. Claire Verschraegen is chair of PCLI’s 12-member steering committee. AACI extends its appreciation to the following steering committee members whose terms ended in 2021 for their time and commitment in guiding the initiative and planning the annual PCLI meeting:

- Dr. Charles Ryan
- Dr. David Gaffney
- Dr. Andrew Chapman

2021 PCLI WEBINARS

“Conducting Virtual Visits and Working with State Licensing Requirements.”

Presenter: Dr. Charles Ryan
Masonic Cancer Center
University of Minnesota

“The Role of the Clinical Pharmacist in an Academic Hematology/Oncology Practice”

Moderator: Dr. Carrie Lee
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Presenters: Drs. Maurice Alexander, Kaitlyn Buhliger, and Kevin Chen
University of North Carolina Medical Center

MEDICAL RECORDS SURVEY

PCLI distributed a 21-question survey to AACI members, titled “The Impact of the 21st Century Cures Act – Immediate Release of Clinical Information (IRCI) on Healthcare Delivery to Cancer Patients.” The survey assessed improvements in access to medical records as a result of IRCI, implemented in April 2021. The survey was distributed to health care providers managing cancer patients, including medical oncology, surgical oncology, radiation oncology, radiology, and pathology providers. It received 167 responses from 37 cancer centers.
AACI SHARES UPDATES AND FACILITATES DISCUSSIONS WITH GOVERNMENT RELATIONS REPRESENTATIVES ON PUBLIC POLICY MATTERS SUCH AS APPROPRIATIONS FOR THE NATIONAL INSTITUTES OF HEALTH (NIH) AND NATIONAL CANCER INSTITUTE (NCI), COVID-19 RELATED POLICIES, AND OTHER FEDERAL ISSUES THAT AFFECT CANCER CENTERS.

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH

A focal point for AACI advocacy in 2021 was the Advanced Research Projects Agency for Health (ARPA-H). Modeled after the Defense Advanced Research Projects Agency (DARPA), the proposed federal agency aims to fill gaps in health care research.

While AACI is optimistic about the adoption of ARPA-H and pleased that President Biden has expressed a desire to make cancer a primary focus of the new agency, the association holds a firm position that any funding for ARPA-H should not be diverted from the NIH or NCI.

In July AACI Executive Director Jennifer W. Pegher spoke at a joint NIH and White House Office of Science and Technology Policy (OSTP) listening session on the topic. AACI also helped develop the One Voice Against Cancer (OVAC) coalition’s principles document on ARPA-H. In addition, AACI’s Executive Committee (Drs. Caryn Lerman, Robert A. Winn, and Roy A. Jensen) met with Dr. Eric Lander, OSTP director, to discuss cancer center concerns about ARPA-H. A letter laying out AACI’s position was sent to Dr. Lander.

Beyond ARPA-H, AACI joined a large coalition in submitting a letter supporting the Research Investment to Spark the Economy (RISE) Act, which would provide at least $10 billion in supplemental funding for the NIH. In June, AACI also sent a letter to the Biden administration outlining AACI’s Fiscal Year (FY) 2022 budget asks, calling for supplemental funding for the NIH and NCI due to COVID-19 research disruptions, and to address health equity and cancer prevention efforts.

A letter laying out AACI’s position was sent to Dr. Lander.

AACI continues to update its Public Policy Resource Library and provide updates on all AACI-endorsed federal legislation on the legislative tracker.

MONTHLY UPDATE CALLS

On the second Thursday of each month AACI hosts a Zoom meeting with cancer center government relations colleagues. The calls allowed AACI members to interact with the following guests about relevant issues.

JANUARY: Dr. Danielle Carnival, member of the HHS agency review team for Biden transition; M.K. Holohan, director, and Holly Gibbons, deputy director, NCI Office of Government & Congressional Relations

FEBRUARY: Melisa Lindamood, director, federal affairs, Johns Hopkins University; Catherine Oakar, special assistant to the president for community, public health, and disparities

MARCH: David Hyssong, founder, SHEPHERD Therapeutics; Mark Ratner, legislative director/deputy chief of staff, Rep. Fred Upton (R-MI)

APRIL: Stephanie Krenrich, director, federal relations, American Cancer Society Cancer Action Network (ACS CAN); Elizabeth Brown, legislative director, Rep. Kathy Castor (D-FL)

MAY: Brett Giroir, MD, distinguished visiting executive, Leavitt Partners; Charlotte Kaye, professional staff member for Senate Health, Education, Labor, and Pensions (HELP) Committee, Senator Richard Burr (R-NC)
**VIRTUAL HILL DAY AND GOVERNMENT RELATIONS FORUM**

In June, AACI co-hosted the 2021 Virtual Hill Day with the American Association for Cancer Research. Ninety-three cancer center directors, researchers, oncologists, survivors, and other advocates, representing 26 states, attended meetings with legislators and staff to present a unified voice in support of stable funding increases for the NIH and NCI.

Representatives Brian Higgins (D-NY) and Gus Bilirakis (R-FL) received the Cancer Research Ally Award during Hill Day and delivered remarks as part of the event’s lunchtime programming.

Representing Buffalo and the Roswell Park Comprehensive Cancer Center, Rep. Higgins has demonstrated his support for cancer research, patients with cancer, and improving the quality of cancer care during 16 years in Congress. He serves as co-chair of the House Cancer Caucus and co-leads the annual “Dear Colleague” letter for NCI funding.

Rep. Bilirakis represents parts of the Tampa Bay area, home to the Moffitt Cancer Center. He has been a strong advocate for the cancer center during his 14 years in Congress and recently was a lead sponsor of the AACI-endorsed CLINICAL TREATMENT Act, which was included in the FY 2021 budget and COVID response package.

AACI’s annual Government Relations (GR) Forum was held in October.

Matthew Swaback, from Sidney Kimmel Cancer Center at Jefferson Health, was announced as the new AACI GR Steering Committee vice chair, effective October 2022. He will succeed current chair John DeMuro, of Moffitt Cancer Center. The event was held in a Zoom webinar format with guests Representative Debbie Wasserman Schultz (D-FL) and Michael Burgess (R-TX), and Dr. Danielle Carnival, of the White House OSTP.

---

**JUNE:** Amy Pellegrino, health policy director, Subcommittee on Primary Health and Retirement Security, Committee on Health, Education, Labor and Pensions, Senator Susan Collins (R-ME); Ansley Rhyne, director of federal affairs, Novo Nordisk

**JULY:** Kyle Robb, PharmD, state policy and advocacy associate, American Society of Health-System Pharmacists

**SEPTEMBER:** Danielle Leach, MPA, chief of community and government relations, National Brain Tumor Society; Tannaz Rasouli, MPH, senior director, public policy and strategic outreach, and Christa Wagner, PhD, senior legislative analyst, Association of American Medical Colleges

**NOVEMBER:** Sarah Owermodic, health care reporter, *Politico*; Heather Ferguson, founder and executive director, Lymphedema Advocacy Group

**DECEMBER:** Ilhaam “Illy” Jaffer, director, federal relations, ACS CAN; Robin Levy, senior director, public policy and advocacy, International Myeloma Foundation; and Jeremy Scott, senior vice president, CRD Associates

---

**Michael Burgess (R-FL)**

**Dr. Danielle Carnival**

**Brian Higgins (D-NY)  Gus Bilirakis (R-FL)**

**Debbie Wasserman Schultz (D-FL)**
THE AACI CORPORATE ROUNDTABLE PROVIDES A FORUM FOR AACI CANCER CENTERS TO ADDRESS TOPICS OF MUTUAL INTEREST WITH INDUSTRY COLLEAGUES.

Through the Corporate Roundtable, cancer centers interact directly with industry decision makers. This interaction leads to support for both new and ongoing AACI programs and initiatives. In 2021, AACI welcomed Fulgent Genetics as a new corporate member.

The AACI Corporate Roundtable met in July during the 13th Annual AACI CRI Meeting and in October at the 2021 AACI/CCAF Annual Meeting. Both meetings were held virtually with discussions focusing on topics such as lessons learned from COVID-19, trial activation, and addressing health disparities in cancer research.

AACI CORPORATE ROUNDTABLE (CRT) TASK FORCE — TRIAL ACTIVATION

In 2021, the AACI CRT Task Force was created to include representatives from AACI’s Corporate Roundtable and the AACI CRI Steering Committee. Three working groups were formed to continue discussions on improving trial activation timelines. The groups met monthly with the goal of finalizing discussion topics for a whitepaper. The working groups are addressing budget negotiations, contract negotiations, trial site committee reviews, and communications.

AACI extends its gratitude for the commitment and support of the 2021 Corporate Roundtable members:
SUPPORTERS

THE AACI/CCAF ANNUAL MEETING AND THE ANNUAL CLINICAL RESEARCH INNOVATION (CRI) MEETING PROVIDED OPPORTUNITIES FOR SUPPORTERS TO INTERACT WITH AACI MEMBERS AND REPRESENTATIVES FROM CANCER RESEARCH-RELATED ORGANIZATIONS.

In 2021, both meetings were held virtually. Supporters and exhibitors utilized the virtual platform to promote their products and services to a record number of meeting attendees including cancer center directors, executive administrators, and leaders of clinics, laboratories, and specialized research facilities.

AACI received support in 2021 for its events, programs, and other activities from:

- Advarra
- American Society of Clinical Oncology (ASCO)
- Caris Life Sciences
- Cedars-Sinai Cancer
- Ciox Health
- Complion
- ECG Management Consultants
- Essex Management
- Florence
- Huron
- nCoup
- Veeva Systems
- WCG Clinical
- WellSky®

13th Annual AACI CRI Meeting Exhibitors
- Advarra
- American Society of Clinical Oncology (ASCO)
- ECG Management Consultants
- Essex Management
- Florence
- Huron
- nCoup
- Veeva Systems
- WCG Clinical
- WellSky®

2021 AACI/CCAF Annual Meeting Exhibitors
- Advarra
- Caris Life Sciences
- ECG
- Florence
- Huron
- nCoup
- The Society for Immunotherapy of Cancer (SITC)
- Veeva Systems
- WCG Clinical
- WellSky®

AACI appreciates the generous investment in our programs made by our many supporters.

SUSTAINING MEMBERS

Sustaining membership in AACI is open to nonprofit organizations that represent and support the educational and professional development of clinical oncology health professionals and researchers. These like-minded cancer organizations and patient advocacy groups share a common goal of accelerating progress against cancer. Sustaining members can take advantage of AACI's resources for educating policymakers on the importance of cancer research funding and are invited to participate in AACI-sponsored meetings, workshops, and forums, and meet annually with AACI leadership.

In 2021 AACI welcomed the Hematology/Oncology Pharmacy Association (HOPA) to its roster of sustaining members. Founded in 2004, HOPA is a professional society for hematology/oncology pharmacists and associates. The organization's mission is to support these pharmacy practitioners and optimize the care of individuals affected by cancer. HOPA also promotes the importance of oncology pharmacists to the cancer care team.

AACI thanks its 2021 sustaining members for their support:
WHILE CONTINUING TO PROVIDE A RELIABLE PLATFORM FOR TIMELY NEWS AND OPINION FROM ITS MEMBER CANCER CENTERS, AACI EXPANDED ITS COMMUNICATIONS EFFORTS ON SEVERAL FRONTS IN 2021.

In July, paid monthly advertisements began to run in the AACI Update newsletter.

The association supported a “Transforming Cancer Care” media campaign with a full-page advertisement touting the unique characteristics of AACI cancer centers. The ad ran in a 16-page magazine insert distributed in 150,000 copies of USA TODAY.

Published monthly, the AACI Update and AACI Commentary—an editorial series focusing on major issues of common interest to North American cancer centers—attracted new readers throughout the year. Notably, the Update published an unprecedented number of job postings in 2021 due to staffing shortages stemming from the ongoing COVID-19 pandemic.

A selection of Commentaries in 2021 examined the following topics:
• COVID-19 vaccination
• Harnessing artificial intelligence to enhance cancer treatment
• Engaging advance practice providers in cancer clinical trials
• Assessing and endorsing cancer-related policy
• The impact of the pandemic on cancer screenings and clinical research

AACI maintained a stable presence on social media, with its Twitter follower count growing to nearly 4,300. Open rates for email communications in the final quarter of 2021 averaged 20 percent.

BRANCHING OUT

In other communications efforts, AACI staff worked closely with data analysts and population scientists at Sidney Kimmel Cancer Center at Jefferson Health to analyze the results of an AACI cancer center catchment area survey and a follow-up survey on cancer center priorities related to Dr. Karen E. Knudsen’s presidential initiative.

In March, AACI released a formal statement condemning racism, discrimination, and gun violence, urging that these issues be confronted as public health crises. In the statement, AACI underscored a commitment to promoting health equity, diversity, and inclusion within North America’s leading cancer centers and in our communities. The association also highlighted the responsibility of its Board of Directors, staff, and cancer center leaders to improve health outcomes for all people—not just as they relate to cancer, but in all facets of public health.

In addition, AACI launched a listserv for community outreach and engagement (COE) professionals at AACI cancer centers. With more than 130 participants at the close of 2021, the listserv provides a platform for members to ask questions or reach out to others about COE-related topics.
NEW MEMBER AND HISTORY PUBLICATION

AACI WELcomed the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine to its Roster, Bringing its Membership to 103 Cancer Centers.

The Meyer Cancer Center (MCC) is directed by Dr. Lewis C. Cantley, AACI’s 2015 Distinguished Scientist awardee. MCC is a matrix cancer center organized by four research focus areas: Cancer Biology; Cancer Genetics & Epigenetics; Experimental Therapeutics; and Cancer Prevention & Control. Its members have primary faculty appointments in 19 departments across Weill Cornell Medicine.

MCC aims to advance the prevention, early detection, and treatment of cancer through scientific discovery; personalized, multidisciplinary patient care; bidirectional community engagement; and cutting-edge training.

AACI’s membership is comprised of academic and freestanding cancer research centers in the United States and Canada. Forming North America’s cancer research infrastructure, AACI cancer centers are recognized worldwide for their excellence in translating promising research findings into new interventions to prevent and treat cancer.

The History of the Association of American Cancer Institutes

To mark the 50th anniversary of the National Cancer Act of 1971, AACI leadership enlisted the services of Dr. Donald L. “Skip” Trump, and journalist Eric T. Rosenthal, coauthors of Centers of the Cancer Universe: A Half-Century of Progress Against Cancer (Rowman & Littlefield, 2021), to research and write a history of AACI examining its origins, growth, development, and accomplishments.

Background was gathered from available sources, particularly AACI’s archives and interviews of past presidents, board members, and other cancer research leaders. Photos of attendees of some of AACI’s earliest gatherings were provided by AACI cancer centers.

An excerpt from the AACI history, highlighting the association’s involvement in the passage and implementation of the National Cancer Act, was featured in the December AACI Commentary.
AACI PRESIDENT
Caryn Lerman, PhD

Dr. Caryn Lerman, director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles, is the new president of AACI.

Dr. Lerman began her two-year term four months early due to Dr. Karen E. Knudsen stepping down in June 2021 as AACI president to become the new chief executive officer of the American Cancer Society.

Dr. Lerman is the associate dean for cancer programs and the H. Leslie and Elaine S. Hoffman Professor in Cancer Research at Keck School of Medicine of USC. She joined the AACI Board of Directors in 2019 and was elected vice president/president-elect in 2020.

“This is a time of rapid change — not only in cancer research, education, and patient care, but also in terms of social justice issues that we must tackle as we elevate our cancer centers and the national cancer program to the next level,” said Dr. Lerman.

“I am looking forward to collaborating with AACI cancer centers to embrace change and address issues that matter most to them, including cancer equity and the diversification of the nation’s oncology leadership pipeline.”

Dr. Lerman’s experience in cancer center leadership spans more than 20 years. Internationally recognized for cancer prevention research that bridges the fields of genomics, pharmacology, and population science, she has deep knowledge of multiple frameworks of cancer discovery and innovation from basic and translational/clinical science to population-based research and biotechnology. A major focus of her research is on biology-driven science to reduce cancer risk behaviors.

An elected member of the National Academy of Medicine, Dr. Lerman has served as a member of the National Cancer Institute Board of Scientific Advisors, the National Human Genome Research Advisory Council, and the National Institute on Drug Abuse Advisory Council. She is also past president of the Society for Research on Nicotine and Tobacco and has received numerous awards for her work, including the American Cancer Society Cancer Control Award, the American Society of Preventive Oncology Joseph Cullen Award, the Alton Ochsner Award Relating Smoking and Health, and the National Institutes of Health Matilda White Riley Award.

AACI PRESIDENT-ELECT
Robert A. Winn, MD

Dr. Robert A. Winn, director of VCU Massey Cancer Center, was elected by AACI’s members in 2021 to serve as vice president/president-elect of AACI’s Board of Directors.

Dr. Winn was appointed to lead VCU Massey in 2019. He previously served as director of the University of Illinois Cancer Center (2015–2019), following 13 years at the University of Colorado Health Sciences Center and School of Medicine in a variety of leadership roles and clinical faculty appointments. Dr. Winn is committed to community-engaged research centered on eliminating health disparities. He is a principal investigator on several community-based projects funded by the National Institutes of Health and National Cancer Institute.

Dr. Winn chaired the 2021 AACI/CCAF Annual Meeting Program Committee and served on the 2020 program committee. He was also the inaugural recipient of the AACI Cancer Health Equity Award.
AACI WELCOMES NEW BOARD MEMBERS

Marcia Cruz-Correa, MD, PhD; Ruben A. Mesa, MD, FACP; and Robert H. Vonderheide, MD, DPhil, were elected as new members of AACI’s Board of Directors, and Anil K. Rustgi, MD, and Joann B. Sweasy, PhD, were appointed to complete the remaining terms of board member Charles S. Fuchs, MD, MPH, (through October 2022) and AACI Vice President/President-elect Robert A. Winn, MD (through October 2023), respectively. David M. Gosky, MA, MBA, succeeded Jeff A. Walker, MBA, as board treasurer.

Dr. Cruz-Correa is the executive director of the University of Puerto Rico (UPR) Comprehensive Cancer Center and leads the center’s Gastrointestinal Oncology Research Program. She is a professor of medicine at the UPR, adjunct associate professor of medicine at Johns Hopkins University, and adjunct professor of surgical oncology at The University of Texas MD Anderson Cancer Center.

Dr. Mesa is the executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, where he is the Mays Family Foundation Distinguished University Presidential Chair. Dr. Mesa has served as the chair of Hematology & Medical Oncology at Mayo Clinic, Arizona, and deputy director of the Mayo Clinic Comprehensive Cancer Center.

Dr. Vonderheide is director of the Abramson Cancer Center and the John H. Glick, MD Abramson Cancer Center’s Director Professor in the Perelman School of Medicine at the University of Pennsylvania. He is vice dean of cancer programs at the Perelman School of Medicine and vice president for cancer programs at the University of Pennsylvania Health System.

Dr. Rustgi was named director of Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center in 2019. He is also Irving Professor of Medicine; associate dean of oncology; and chief of cancer services.

Dr. Sweasy was appointed director of the University of Arizona Cancer Center (UACC) in 2020. She is the inaugural holder of the Nancy C. and Craig M. Berge Endowed Chair for the Director of the UACC and was recruited from Yale Cancer Center where she served as a member of the faculty for 26 years.

David M. Gosky, MA, MBA, is the executive director of administration at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.

Outgoing Board Members
AACI thanks outgoing board members Randall F. Holcombe, MD, MBA; Thomas P. Loughran, Jr., MD; and Leonidas C. Platanias, MD, PhD; and Treasurer Jeff A. Walker, MBA. Dr. Holcombe is director of the University of Vermont Cancer Center. He chaired the 2018 AACI/CCAF Annual Meeting Program Committee and AACI’s Physician Clinical Leadership Initiative and served on AACI’s CRI Steering Committee and Conflict of Interest (COI) Task Force. Dr. Loughran is director of UVA Cancer Center in Charlottesville, Virginia, and previously served as the founding director of Penn State Cancer Institute. Dr. Platanias leads Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago. He co-chaired AACI’s COI Task Force and served on the 2019 annual meeting program committee. Walker is executive vice president of Roswell Park Comprehensive Cancer Center and previously served as chief operating officer at City of Hope National Medical Center.
2021 COMMITTEES

ANNUAL MEETING

Chair: Robert A. Winn, MD
VCU Massey Cancer Center

S. Gail Eckhardt, MD, FASCO
Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School

Matthew Hussey, MBA, DBA
Sidney Kimmel Cancer Center at Jefferson Health

Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Jennifer W. Pegher
Association of American Cancer Institutes

Anil K. Rustgi, MD
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Julie C. Sehaum, MS
Vanderbilt-Ingram Cancer Center

Kate Shumate, MPA, CCRP
UCSF Helen Diller Family Comprehensive Cancer Center

Cornelia Ulrich, PhD, MS
Huntsman Cancer Institute
University of Utah

Robert H. Vanderheide, MD, DPhil
Abramson Cancer Center of the University of Pennsylvania

Jane Welter, MBA
Mayo Clinic Cancer Center

CONFLICT OF INTEREST

Chair: Karen E. Knudsen, PhD, MBA
American Cancer Society

Co-chair: Leonidas C. Platanias, MD, PhD
Robert H. Lurie Comprehensive Cancer Center at Northwestern University

James H. Doroshow, MD
National Cancer Institute

Robert L. Ferris, MD
UPMC Hillman Cancer Center

Randall F. Holcombe, MD, MBA
The University of Vermont Cancer Center

Clifford A. Hudis, MD, FACP, FASCO
American Society of Clinical Oncology

Roy A. Jensen, MD
The University of Kansas Cancer Center

Candace S. Johnson, PhD
Roswell Park Comprehensive Cancer Center

Dina Michels, JD
American Society of Clinical Oncology

Pamela Munster, MD
UCSF Helen Diller Family Comprehensive Cancer Center

Jennifer W. Pegher
Association of American Cancer Institutes

Patricia M. Wiley
On the Wings of Angels

CRI STEERING COMMITTEE

Chair: Theresa L. Werner, MD
Huntsman Cancer Institute
University of Utah

Vice Chair: Tara Lin, MD
The University of Kansas Cancer Center

Tiffany Colvin, CCRP
University of Colorado Cancer Center

Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Janie Hofacker, RN, BSN, MS
Association of American Cancer Institutes

Collette Houston
Memorial Sloan Kettering Cancer Center

Kimberly F. Kerstann, PhD
Winship Cancer Institute of Emory University

Patricia M. Loftusso, DO, PhD
Yale Cancer Center
Yale School of Medicine

Melissa Nashwati, MPA
Mayo Cancer Center at UT Health San Antonio MD Anderson

Blau Pappu, PhD, MHA
UT Southwestern Medical Center

Jennifer W. Pegher
Association of American Cancer Institutes

Michael Sainz
Dartmouth-Hitchcock Norris Cotton Cancer Center

Anne Schnatterly, MBA, BSN, RN, CCRP
WWV Cancer Institute

CRI SHARED INVESTIGATOR PLATFORM TASK FORCE

Chair: Theresa L. Werner, MD
Huntsman Cancer Institute
University of Utah

Jackie Anstead
The University of Chicago Medicine
Comprehensive Cancer Center

Susan Barry
Dana-Farber Cancer Institute
Harvard Medical School

Sarah Bigelow, CCRP
Barbara Ann Karmanos Cancer Institute
Wayne State University

Christine Champagne
Dana-Farber Cancer Institute
Harvard Medical School

Nicholas Cimaglia
Memorial Sloan Kettering Cancer Center

Dina Aziz, MSHS
The University of Texas MD Anderson Cancer Center

Wendy Bloomer, PhD, CCRP
Duke Cancer Institute
Duke University Medical Center

Deidre Cleary, RN, BSN, CCRP
UPMC Hillman Cancer Center

Megan Farmer, MS
Wake Forest Baptist Comprehensive Cancer Center

Chloe Fournier
Duke Cancer Institute
Duke University Medical Center

Caryn Jerome
Sidney Kimmel Cancer Center at Jefferson Health

Fyalon Kerr, CCRP
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Rachel Kingsford, MS, CCRP
Huntsman Cancer Institute
University of Utah

Erin E. Lynch, MS, CCRP
Dartmouth-Hitchcock Norris Cotton Cancer Center

Kim Nguyen
Winship Cancer Institute of Emory University

Sarah Osipowicz, MSeD, CCRP
Sidney Kimmel Cancer Center at Jefferson Health

Nishita Parekh
Princess Margaret Cancer Centre
University Health Network

Cary Passaglia, CCRP
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Helen Peck, RN, MA, OCN, CCRP
Wilmot Cancer Institute
UR Medicine

Elizabeth Pon, CCRP
UCSF Helen Diller Family Comprehensive Cancer Center

Claire Sulkowski, CCRP
Dana-Farber Cancer Institute
Harvard Medical School

Evan Yu, MD
Fred Hutchinson Cancer Research Center

CRI EDUCATION AND OPERATIONS SUBCOMMITTEE

Alexandra Amnis, CCRP
The University of Kansas Cancer Center

20
Tiffany Colvin
University of Colorado Cancer Center

Theresa Cummings, RN, MS, CCRP
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Joeys Felts, CCRP
Sideman Cancer Center

Angela Fritzsche, MPA
Mayo Clinic Cancer Center

Stefan C. Grant, MD, JD, MBA
Wake Forest Baptist Comprehensive Cancer Center

Joseph Hines II, MPH
The University of Kansas Cancer Center

Ginny Keeling, MS
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Nadia Maknou
Laura and Isaac Perlmutter Cancer Center at NYU Langone

Jessica Moehle, CCRP
Huntsman Cancer Institute
University of Utah

Erin Nelson, MPH, CCRP
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

Lindsay Philip
Princess Margaret Cancer Centre
University Health Network

Cammy Pilareczuk
Cleveland Clinic Cancer Center

Erika Pruzzi
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

James Shuck
Barbara Ann Karmanos Cancer Institute
Wayne State University

Kendra Todd, MBA
OHSU Knight Cancer Institute

Christine Vollmer, MBA
University of Cincinnati Cancer Center

Amber L. Voorhees
Moffitt Cancer Center

Leslie Waitkus, BSN, CCRP
Cleveland Clinic Cancer Center

CRI CTO MEDICAL DIRECTORS

Chair: Theresa L. Werner, MD
Huntsman Cancer Institute
University of Utah

Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Stephan C. Grant, MD, JD, MBA
Wake Forest Baptist Comprehensive Cancer Center

Tara Lin, MD
The University of Kansas Cancer Center

Patricia M. LoRusso, DO, PhD
Yale Cancer Center
Yale School of Medicine

FINANCE AND INVESTMENT

Chair: Jeff A. Walker, MBA
Roswell Park Comprehensive Cancer Center

David M. Gosky, MA, MBA
The Ohio State University
Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

Patrick O’Brien, MBA
Fox Chase Cancer Center, Temple Health

Joanna Weiss, CPA
Moffitt Cancer Center

GOVERNMENT RELATIONS

Chair: John DeMuro
Moffitt Cancer Center

Vice Chair: Matthew Swaback
Sidney Kimmel Cancer Center at Jefferson Health

David B. Brown, MSHA
USC Norris Comprehensive Cancer Center

Jill Homer Stewart
The Jackson Laboratory Cancer Center

James Kennedy
Roswell Park Comprehensive Cancer Center

Alex M. Krigstein
University of Florida Health Cancer Center

Catherine Liao
Duke Cancer Institute
Duke University Medical Center

Peter J. Macker
City of Hope Comprehensive Cancer Center

Kent Springfield
UCLA Jonsson Comprehensive Cancer Center

LEADERSHIP DEVELOPMENT INITIATIVE

Chair: Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

David M. Gosky, MA, MBA
The Ohio State University
Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

Chantita Hughes Halbert, PhD
USC Norris Comprehensive Cancer Center

Roy A. Jensen, MD
The University of Kansas Cancer Center

Kelvin Lee, MD
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Edith P. Mitchell, MD, FACP, FCPP
Sidney Kimmel Cancer Center at Jefferson Health

Kunle Odunsi, MD, PhD, FRCOG, FACOG
The University of Chicago Medicine
Comprehensive Cancer Center

PCLI STEERING COMMITTEE

Chair: Claire Verschraegen, MS, MD, FACP
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute

Thaker Abu Hejleh, MBBS, MS
Holden Comprehensive Cancer Center
University of Iowa

Steven R. Alberts, MD
Mayo Clinic Cancer Center

Julie R. Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Andrew Chapman, DO, FACP
Sidney Kimmel Cancer Center at Jefferson Health

David Gaffney, MD
Huntsman Cancer Institute
University of Utah

Carrie Lee, MD, MPH
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Merry-Jennifer Markham, MD, FACP
University of Florida Health Cancer Center

Karen L. Reckamp, MD, MS
Cedars-Sinai Cancer Center

Charles J. Ryan, MD
Masonic Cancer Center
University of Minnesota

Julie Ann Sosa, MD, MA, FACS, MAMSE, FSSO
UCSF Helen Diller Family Comprehensive Cancer Center

John Sweetenham, MD, FRCP, FACP, FASCO
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
2021 MEMBERS

United States

ALABAMA
O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Birmingham, Alabama

ARIZONA
Mayo Clinic Cancer Center, Arizona
Scottsdale, Arizona
The University of Arizona Cancer Center
Tucson, Arizona

ARKANSAS
UAMS Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas

CALIFORNIA
Cedars-Sinai Cancer
Los Angeles, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Cancer Center
Loma Linda, California
Salk Institute Cancer Center
La Jolla, California
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, California
Stanford Cancer Institute
Palo Alto, California
UC Davis Comprehensive Cancer Center
Sacramento, California
UC San Diego Moores Cancer Center
La Jolla, California
UCI Chao Family Comprehensive Cancer Center
Orange, California
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
USC Norris Comprehensive Cancer Center
Los Angeles, California

COLORADO
University of Colorado Cancer Center
Aurora, Colorado

CONNECTICUT
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

DISTRICT OF COLUMBIA
Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia
GW Cancer Center
Washington, District of Columbia

FLORIDA
Mayo Clinic Cancer Center, Florida
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Sylvester Comprehensive Cancer Center
University of Miami Health System
Miami, Florida
University of Florida Health Cancer Center
Gainesville, Florida

GEORGIA
Georgia Cancer Center, Augusta University
Augusta, Georgia
Winship Cancer Institute of Emory University
Atlanta, Georgia

HAWAI’I
University of Hawai’i Cancer Center
Honolulu, Hawai’i

ILLINOIS
Cancer Center at Illinois
Urbana, Illinois
Cardinal Bernardin Cancer Center
Loyola University Medical Center
Maywood, Illinois
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
The University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois
University of Illinois Cancer Center
Chicago, Illinois

INDIANA
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Purdue University Center for Cancer Research
West Lafayette, Indiana

IOWA
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

KANSAS
The University of Kansas Cancer Center
Kansas City, Kansas

KENTUCKY
UK Markey Cancer Center
Lexington, Kentucky
UofL James Graham Brown Cancer Center
Louisville, Kentucky

LOUISIANA
Feist–Weiller Cancer Center
LSU Health Shreveport
Shreveport, Louisiana
Louisiana Cancer Research Center
New Orleans, Louisiana

MAINE
The Jackson Laboratory Cancer Center
Bar Harbor, Maine

MARYLAND
Muirth Cancer Center at Walter Reed Bethesda
Bethesda, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland

MASSACHUSETTS
Boston University Cancer Center
Boston, Massachusetts
Dana–Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

MICHIGAN
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
The University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

MINNESOTA
Masonic Cancer Center
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota

MISSISSIPPI
UMMC Cancer Center and Research Institute
Jackson, Mississippi

MISSOURI
Siteman Cancer Center
St. Louis, Missouri

NEBRASKA
Fred and Pamela Buffett Cancer Center
Omaha, Nebraska

NEW HAMPSHIRE
Dartmouth-Hitchcock Norris Cotton Cancer Center
Lebanon, New Hampshire

NEW JERSEY
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
NEW MEXICO
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico

NEW YORK
Albert Einstein Cancer Center
Albert Einstein College of Medicine
Bronx, New York
Cold Spring Harbor Laboratory Cancer Center
Cold Spring Harbor, New York
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center
New York, New York
Laura and Isaac Perlmutter Cancer Center
NYU Langone
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York
Stony Brook Cancer Center
Stony Brook, New York
The Tisch Cancer Institute at Mount Sinai
New York, New York
Upstate Cancer Center
SUNY Upstate Medical University
Syracuse, New York
Wilmot Cancer Institute
UR Medicine
Rochester, New York

NORTH CAROLINA
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina

OHIO
Case Comprehensive Cancer Center
Cleveland, Ohio
Cleveland Clinic Cancer Center
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, Ohio
University of Cincinnati Cancer Center
Cincinnati, Ohio

OKLAHOMA
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, Oklahoma

OREGON
OHSU Knight Cancer Institute
Portland, Oregon

PENNSYLVANIA
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Penn State Cancer Institute
Hershey, Pennsylvania
Sidney Kimmel Cancer Center at Jefferson Health
Philadelphia, Pennsylvania
The Wistar Institute
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

PUERTO RICO
University of Puerto Rico Comprehensive Cancer Center
San Juan, Puerto Rico

RHODE ISLAND
Legorreta Cancer Center at Brown University
Providence, Rhode Island

SOUTH CAROLINA
Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina

TENNESSEE
Comprehensive Cancer Center
St. Jude Children’s Research Hospital
Memphis, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

TEXAS
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine
Houston, Texas
Livestrong Cancer Institutes
The University of Texas at Austin Dell Medical School
Austin, Texas
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Texas Medical Branch Cancer Center
Galveston, Texas

UTAH
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

VERMONT
The University of Vermont Cancer Center
Burlington, Vermont

VIRGINIA
University of Virginia Cancer Center
Charlottesville, Virginia
VCU Massey Cancer Center
Richmond, Virginia

WASHINGTON
Fred Hutchinson Cancer Research Center
Seattle, Washington

WEST VIRGINIA
WVU Cancer Institute
Morgantown, West Virginia

WISCONSIN
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Canada

BRITISH COLUMBIA
BC Cancer
Vancouver, British Columbia

ONTARIO
Princess Margaret Cancer Centre
University Health Network
Toronto, Ontario